Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects

Kyoung Ah Kim, Pil Whan Park, Ock Je Lee, Dong Kyun Kang, Ji-Young Park

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Simvastatin, a cholesterol-lowering agent, is mainly metabolized by CYP3A4/5. The objective of this study was to investigate the effect of CYP3A5*3 genotype on the pharmacokinetics of simvastatin in humans. Twenty-two men with CYP3A5*1/*1 (n = 4), CYP3A5*1/*3 (n = 8), or CYP3A5*3/*3 (n = 10) genotypes were enrolled. Each subject ingested a 20-mg dose of simvastatin, and plasma simvastatin concentrations were measured for 12 hours after dosing. The mean (±SD) area under the plasma concentration-time curve for simvastatin in the CYP3A5*1/*1 carriers (4.94 ± 2.25 ng·h/mL) was significantly lower than CYP3A5*3/*3 carriers (16.35 ± 6.37 ng·h/mL; P =.013, Bonferroni test). The mean (±SD) oral clearance was also significantly different between CYP3A5*1/*1 carriers (4.80 ± 2.35 L/h) and CYP3A5*3/*3 carriers (1.35 ± 0.61 L/h; P <.05, Dunn's test). However, other pharmacokinetic parameters including peak plasma concentrations and half-life did not show any difference between genotype groups. These findings suggest that the polymorphic CYP3A5 gene affects the disposition of simvastatin and provides a plausible explanation for interindividual variability of simvastatin disposition.

Original languageEnglish
Pages (from-to)87-93
Number of pages7
JournalJournal of Clinical Pharmacology
Volume47
Issue number1
DOIs
Publication statusPublished - 2007 Jan 1

Fingerprint

Cytochrome P-450 CYP3A
Simvastatin
Healthy Volunteers
Pharmacokinetics
Genotype
Half-Life
Cholesterol

Keywords

  • CYP3A5*3
  • Cytochrome P450 3A5 (CYP3A5)
  • Pharmacogenetics
  • Pharmacokinetics
  • Simvastatin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. / Kim, Kyoung Ah; Park, Pil Whan; Lee, Ock Je; Kang, Dong Kyun; Park, Ji-Young.

In: Journal of Clinical Pharmacology, Vol. 47, No. 1, 01.01.2007, p. 87-93.

Research output: Contribution to journalArticle

Kim, Kyoung Ah ; Park, Pil Whan ; Lee, Ock Je ; Kang, Dong Kyun ; Park, Ji-Young. / Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. In: Journal of Clinical Pharmacology. 2007 ; Vol. 47, No. 1. pp. 87-93.
@article{9a0656f06d0740c09d557ec2dcf4e372,
title = "Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects",
abstract = "Simvastatin, a cholesterol-lowering agent, is mainly metabolized by CYP3A4/5. The objective of this study was to investigate the effect of CYP3A5*3 genotype on the pharmacokinetics of simvastatin in humans. Twenty-two men with CYP3A5*1/*1 (n = 4), CYP3A5*1/*3 (n = 8), or CYP3A5*3/*3 (n = 10) genotypes were enrolled. Each subject ingested a 20-mg dose of simvastatin, and plasma simvastatin concentrations were measured for 12 hours after dosing. The mean (±SD) area under the plasma concentration-time curve for simvastatin in the CYP3A5*1/*1 carriers (4.94 ± 2.25 ng·h/mL) was significantly lower than CYP3A5*3/*3 carriers (16.35 ± 6.37 ng·h/mL; P =.013, Bonferroni test). The mean (±SD) oral clearance was also significantly different between CYP3A5*1/*1 carriers (4.80 ± 2.35 L/h) and CYP3A5*3/*3 carriers (1.35 ± 0.61 L/h; P <.05, Dunn's test). However, other pharmacokinetic parameters including peak plasma concentrations and half-life did not show any difference between genotype groups. These findings suggest that the polymorphic CYP3A5 gene affects the disposition of simvastatin and provides a plausible explanation for interindividual variability of simvastatin disposition.",
keywords = "CYP3A5*3, Cytochrome P450 3A5 (CYP3A5), Pharmacogenetics, Pharmacokinetics, Simvastatin",
author = "Kim, {Kyoung Ah} and Park, {Pil Whan} and Lee, {Ock Je} and Kang, {Dong Kyun} and Ji-Young Park",
year = "2007",
month = "1",
day = "1",
doi = "10.1177/0091270006295063",
language = "English",
volume = "47",
pages = "87--93",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects

AU - Kim, Kyoung Ah

AU - Park, Pil Whan

AU - Lee, Ock Je

AU - Kang, Dong Kyun

AU - Park, Ji-Young

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Simvastatin, a cholesterol-lowering agent, is mainly metabolized by CYP3A4/5. The objective of this study was to investigate the effect of CYP3A5*3 genotype on the pharmacokinetics of simvastatin in humans. Twenty-two men with CYP3A5*1/*1 (n = 4), CYP3A5*1/*3 (n = 8), or CYP3A5*3/*3 (n = 10) genotypes were enrolled. Each subject ingested a 20-mg dose of simvastatin, and plasma simvastatin concentrations were measured for 12 hours after dosing. The mean (±SD) area under the plasma concentration-time curve for simvastatin in the CYP3A5*1/*1 carriers (4.94 ± 2.25 ng·h/mL) was significantly lower than CYP3A5*3/*3 carriers (16.35 ± 6.37 ng·h/mL; P =.013, Bonferroni test). The mean (±SD) oral clearance was also significantly different between CYP3A5*1/*1 carriers (4.80 ± 2.35 L/h) and CYP3A5*3/*3 carriers (1.35 ± 0.61 L/h; P <.05, Dunn's test). However, other pharmacokinetic parameters including peak plasma concentrations and half-life did not show any difference between genotype groups. These findings suggest that the polymorphic CYP3A5 gene affects the disposition of simvastatin and provides a plausible explanation for interindividual variability of simvastatin disposition.

AB - Simvastatin, a cholesterol-lowering agent, is mainly metabolized by CYP3A4/5. The objective of this study was to investigate the effect of CYP3A5*3 genotype on the pharmacokinetics of simvastatin in humans. Twenty-two men with CYP3A5*1/*1 (n = 4), CYP3A5*1/*3 (n = 8), or CYP3A5*3/*3 (n = 10) genotypes were enrolled. Each subject ingested a 20-mg dose of simvastatin, and plasma simvastatin concentrations were measured for 12 hours after dosing. The mean (±SD) area under the plasma concentration-time curve for simvastatin in the CYP3A5*1/*1 carriers (4.94 ± 2.25 ng·h/mL) was significantly lower than CYP3A5*3/*3 carriers (16.35 ± 6.37 ng·h/mL; P =.013, Bonferroni test). The mean (±SD) oral clearance was also significantly different between CYP3A5*1/*1 carriers (4.80 ± 2.35 L/h) and CYP3A5*3/*3 carriers (1.35 ± 0.61 L/h; P <.05, Dunn's test). However, other pharmacokinetic parameters including peak plasma concentrations and half-life did not show any difference between genotype groups. These findings suggest that the polymorphic CYP3A5 gene affects the disposition of simvastatin and provides a plausible explanation for interindividual variability of simvastatin disposition.

KW - CYP3A53

KW - Cytochrome P450 3A5 (CYP3A5)

KW - Pharmacogenetics

KW - Pharmacokinetics

KW - Simvastatin

UR - http://www.scopus.com/inward/record.url?scp=33845806096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845806096&partnerID=8YFLogxK

U2 - 10.1177/0091270006295063

DO - 10.1177/0091270006295063

M3 - Article

VL - 47

SP - 87

EP - 93

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 1

ER -